CARDIFF ONCOLOGY, INC. Proceeds from Debt, Net of Issuance Costs
CARDIFF ONCOLOGY, INC. (CRDF) reported Proceeds from Debt, Net of Issuance Costs of $0 for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2017-11-09
- 2017-09-30: Proceeds from Debt, Net of Issuance Costs 9 month $0.00.
- 2016-09-30: Proceeds from Debt, Net of Issuance Costs 9 month $7.81M.
- 2015-09-30: Proceeds from Debt, Net of Issuance Costs 9 month $0.00.
| Period end | Proceeds from Debt, Net of Issuance Costs 9 month |
|---|---|
| 2017-09-30 | $0.00 10-Q · filed 2017-11-09 |
| 2016-09-30 | $7.81M 10-Q · filed 2017-11-09 |
| 2015-09-30 | $0.00 10-Q · filed 2016-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |